Sarepta Therapeutics SRPT
NASDAQ SRPT
$17.58 -0.60 (-3.30%)
As of: Oct 23, 2026 · 3:38 PM EDT

Sarepta Therapeutics (SRPT) Gains from Equity Investments (2023)

Updated

Analysis

Sarepta Therapeutics (SRPT) Gains from Equity Investments (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,130.49 Bn 1,099.07 Bn 19.71 Bn
2 Johnson & Johnson 635.65 Bn 555.51 Bn 17.30 Bn
3 AbbVie 505.44 Bn 478.55 Bn 12.70 Bn
4 Merck 358.27 Bn 312.65 Bn 12.21 Bn
5 Novartis Ag 291.57 Bn 255.56 Bn 11.24 Bn
6 Astrazeneca 265.15 Bn 238.84 Bn 12.86 Bn
7 Amgen 237.41 Bn 192.81 Bn 7.24 Bn
8 Gilead Sciences 195.01 Bn 169.21 Bn 6.22 Bn
9 Pfizer 171.23 Bn 117.87 Bn 10.94 Bn
10 Sarepta Therapeutics 1.85 Bn -1.38 Bn 251.87 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -2.50 Mn
API Access

Sarepta Therapeutics Gains from Equity Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-equity-investments&ticker=SRPT&period=max&api_key=YOUR_API_KEY